|
10359
|
RSV F vaccine
|
Respiratory syncytial virus infection
|
Respiratory
|
Respiratory syncytial virus
|
negative-sense, single-stranded RNA
|
Live-attenuated
|
Phase 3
|
Novavax Inc.
|
2020
|
USA
|
18 - 40 years
|
2 doses 9 months apart
|
Intramuscular
|
Aluminum
|
RSV surface glycoprotein
|
NA
|
NA
|
Bill and Melinda Gates Foundation
|
NA
|
NA
|
NA
|
NCT02624947
|
https://clinicaltrials.gov/ct2/show/NCT02624947?recrs=bde&cond=Respiratory+Syncytial+Virus+%28RSV%29&phase=23&draw=2&rank=2
|
NA
|
|
10360
|
Motavizumab
|
Respiratory syncytial virus infection
|
Respiratory
|
Respiratory syncytial virus
|
negative-sense, single-stranded RNA
|
Protein subunit
|
Phase 3
|
MedImmune LLC
|
2013
|
USA
|
upto 1 year
|
5 doses in interval for 1 month
|
Intramuscular
|
NA
|
Fusion glycoprotein of RSV
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NCT00129766
|
https://clinicaltrials.gov/ct2/show/NCT00129766?recrs=bde&cond=Respiratory+Syncytial+Virus+%28RSV%29&phase=23&draw=2&rank=3
|
NA
|
|
10361
|
Ad26. RSV. preF
|
Respiratory syncytial virus infection
|
Respiratory
|
Respiratory syncytial virus
|
negative-sense, single-stranded RNA
|
Recombinant viral vector
|
Phase 3
|
Janssen Pharmaceutical
|
2021
|
USA
|
18 - 59 years
|
2 doses 6 months apart
|
Intramuscular
|
NA
|
Fusion glycoprotein of RSV
|
NA
|
US FDA
|
NA
|
NA
|
NA
|
NA
|
NCT05070546
|
https://clinicaltrials.gov/ct2/show/NCT05070546?recrs=bde&cond=Respiratory+Syncytial+Virus+%28RSV%29&phase=23&draw=2&rank=8
|
https://www.fda.gov/media/105619/download
|
|
10362
|
MK-1654
|
Respiratory syncytial virus infection
|
Respiratory
|
Respiratory syncytial virus
|
negative-sense, single-stranded RNA
|
NA
|
Phase 3
|
Merck & Co. Inc.
|
2021
|
USA
|
upto 1 year
|
NA
|
Intramuscular
|
NA
|
Fusion glycoprotein of RSV
|
NA
|
US FDA
|
NA
|
NA
|
NA
|
NA
|
NCT04938830
|
https://clinicaltrials.gov/ct2/show/NCT04938830?recrs=bde&cond=Respiratory+Syncytial+Virus+%28RSV%29&phase=23&draw=2&rank=12
|
https://ichgcp.net/clinical-trials-registry/NCT04938830
|